Mumbai, April 27 -- According to the company's exchange filing, Sun Pharma would acquire 100% of Organon's issued and outstanding shares for cash at a price of $14 per share, aggregating to approximately $3.99 billion in total equity value.

The company plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction is expected to close in early 2027.

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021.

Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women's health, the company's portfolio includes m...